Articles

Articles by KidNEYCAnCeR June 17, 2026

ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights

doi.org/10.52733/ASCO26Summary Thomas E. Hutson, DO, PharmD, FACP Editor-in-Chief, Kidney Cancer Journal A Summary Report for the Global Oncology Community Chicago, Illinois | May 29 – June 2, 2026 | Kidney Cancer Journal, Volume 24…

144Views 0Comments

Most Clinically Significant Kidney Cancer Presentations from ASCO 2026

Selected by the Editor-in-Chief | Kidney Cancer Journal, Volume 24(2) Primary data drawn from ASCO 2026 presentations, JCO supplement abstracts, press releases, and peer-reviewed commentary. Abstract 1 — LBA418 LITESPARK-022: Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Clear…

Articles Latest Issue new blog by KidNEYCAnCeR May 25, 2026

582Views 0Comments

Renal Cell Carcinoma at the ASCO 2026 Inflection Point -Pre-meeting Preview

May 29–June 2, 2026 | Chicago, IL Senthil Pazhanisamy, BPharma, MS, PhD. Overview The 2026 ASCO Annual Meeting arrives at a critical inflection point for renal cell carcinoma (RCC). The February ASCO GU Symposium in San Francisco delivered a rapid sequence of…

Articles by KidNEYCAnCeR May 21, 2026

133Views 0Comments

Modifiable risk factors for kidney cancer among adults in India: A systematic review to recommend the most effective preventive measures for kidney cancer in India.

Nitinkumar Moradiya University Of Sunderland, Harbour Exchange Square, E14 9GE, London, United Kingdom. ABSTRACT Background: Kidney cancer is an emerging public health concern in India, with rising incidence rates and a significant economic burden. While global research has identified common risk…

Articles by KidNEYCAnCeR April 20, 2026

572Views 0Comments

Molecular and Genomic Biomarkers in Small Renal Masses: A Narrative Review

This narrative review summarizes the current evidence for molecular and genomic biomarkers in SRM risk stratification and evaluates their potential clinical role.

2020 2021 2022 2023 2024 2025 Articles by KidNEYCAnCeR April 2, 2026

628Views 0Comments

Heading One

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…

Articles by KidNEYCAnCeR April 1, 2026

580Views 0Comments

thank-you

Thank you for subscribing to the Kidney Cancer Journal. You're now part of a community dedicated to advancing research, treatment, and hope. We'll be in touch soon

Articles by KidNEYCAnCeR February 21, 2026

702Views 0Comments

The Future of RCC Treatment

Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD The Kidney Cancer Journal is pleased to receive and review the expert consensus manuscript stemming from the IKCSEU24 Think…

Articles by KidNEYCAnCeR February 20, 2026

1149Views 0Comments

Kidney Cancer Summary from ASCO 2025: Therapies, Biomarkers, and Beyond

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…

Articles by KidNEYCAnCeR February 20, 2026

712Views 0Comments

The New Frontier: Advancements in Kidney Cancer Treatment

Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD Dear colleagues, The landscape of kidney cancer treatment is in a state of rapid and thrilling evolution. As editors,…

Articles

ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights

Most Clinically Significant Kidney Cancer Presentations from ASCO 2026

Renal Cell Carcinoma at the ASCO 2026 Inflection Point -Pre-meeting Preview

Modifiable risk factors for kidney cancer among adults in India: A systematic review to recommend the most effective preventive measures for kidney cancer in India.

Molecular and Genomic Biomarkers in Small Renal Masses: A Narrative Review

Heading One

thank-you

The Future of RCC Treatment

Kidney Cancer Summary from ASCO 2025: Therapies, Biomarkers, and Beyond

The New Frontier: Advancements in Kidney Cancer Treatment

About Us

Contents

Follow Us

Guidelines

Patient Resources